EN
Insmed: Can Brinsupri Sustain Growth Without Launch Backlog Patients?
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Insmed typically reports earnings before the market opens, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-08-06 | +$33.53 (+33.86%) | $11.55 (11.66%) | -$1.45 (-1.09%) | $9.05 (6.82%) |
| 2026-05-07 | -$32.09 (-23.41%) | $21.86 (15.95%) | -$3.65 (-3.48%) | $9.65 (9.19%) |
| 2026-02-19 | +$9.89 (+6.54%) | $15.88 (10.51%) | +$3.91 (+2.43%) | $9.60 (5.96%) |
| 2025-10-30 | +$27.27 (+16.33%) | $27.70 (16.59%) | -$4.62 (-2.38%) | $10.06 (5.18%) |
| 2025-08-07 | -$1.96 (-1.76%) | $5.40 (4.85%) | +$0.25 (+0.23%) | $2.81 (2.57%) |
| 2025-05-08 | -$2.65 (-3.88%) | $4.27 (6.25%) | -$0.55 (-0.84%) | $1.96 (2.99%) |
| 2025-02-20 | -$0.22 (-0.26%) | $4.78 (5.70%) | -$2.55 (-3.05%) | $4.48 (5.36%) |
| 2024-10-31 | -$3.02 (-4.29%) | $3.34 (4.75%) | +$1.04 (+1.55%) | $2.93 (4.35%) |
| Avg Abs Move | 11.29% | 9.53% | 1.88% | 5.30% |
Historical price behavior around earnings reveals extreme volatility, with the stock averaging an 11.29% absolute move on Day 0 and a more modest 1.88% move on Day +1. The Day 0 range averages 9.53%, indicating substantial intraday swings as investors digest results.
Recent reports have delivered particularly dramatic moves. The August 2026 report triggered a +33.86% surge on Day 0 following the strong earnings beat, while the May 2026 report produced a -23.41% decline after that quarter's miss. Earlier reports in the sequence showed more moderate reactions, with moves ranging from -4.29% to +16.33%.
The pattern suggests INSM is a high-beta earnings play where execution relative to expectations drives outsized price action. Investors should prepare for significant volatility, particularly given the stock's current position near 52-week lows and the market's focus on the Japan launch trajectory.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 11/20/26 (DTE 23) |
| Expected Move | $13.51 (13.93%) |
| Expected Range | $83.47 to $110.49 |
| Implied Volatility | 85.07% |
The options market is pricing an expected move of ±13.93% for the November expiration, which sits above the stock's average historical Day 0 move of 11.29% but below the most extreme recent reactions. This suggests options traders are anticipating elevated volatility but not the 30%+ swings seen in the last two reports, potentially reflecting reduced conviction about a major surprise in either direction.
Part 3: What Analysts Are Saying
Analysts maintain a strongly bullish stance on Insmed despite the stock's recent weakness. The consensus rating stands at 4.76 out of 5.0, with 21 Strong Buy ratings, 2 Moderate Buy ratings, and 2 Hold ratings—no analysts recommend selling the stock. The average price target of $192.22 implies 98% upside from the current price of $96.98, with targets ranging from a low of $106.00 to a high of $243.00.
However, sentiment has deteriorated slightly over the past month, with the average recommendation slipping from 4.84 to 4.76 as one analyst downgraded from Strong Buy to Hold. The total analyst count remains steady at 25, indicating sustained Wall Street coverage despite the stock's decline.
The wide dispersion in price targets—spanning from $106 to $243—reflects divergent views on the company's timeline to profitability and the ultimate commercial potential of its pipeline. Bulls see the Japan launch and pipeline progress supporting the $5+ billion peak sales case for BRINSUPRI alone, while more cautious analysts appear focused on near-term execution risk and the path to positive cash flow. The consensus view clearly favors the optimistic scenario, with 92% of analysts rating the stock a Buy or Strong Buy.
Part 4: Technical Picture
Insmed enters earnings in a technically challenged position, with the Barchart Technical Opinion showing an 88% Sell signal—unchanged from last week but significantly deteriorated from the 40% Sell signal one month ago. This sharp shift reflects the stock's sustained downtrend as it trades near its 52-week low of $90.39.
Timeframe Analysis:
- Short-term (100% Sell): Strong sell signal indicates near-term momentum is decisively negative heading into the report
- Medium-term (50% Sell): Moderate sell signal suggests intermediate-term weakness, though less extreme than the short-term reading
- Long-term (100% Sell): Strong sell signal reflects persistent weakness across the longer-term trend structure
Trend Characteristics: The combination of Average strength and Average direction suggests the downtrend is neither accelerating nor showing signs of exhaustion, creating an uncertain technical backdrop for earnings.
The moving average structure confirms the bearish setup. The stock at $96.98 trades above only the 5-day ($94.74) and 10-day ($95.42) moving averages, while sitting below the 20-day ($98.95), 50-day ($113.29), 100-day ($111.08), and 200-day ($125.93) averages. This configuration—with all major moving averages in descending order above the current price—defines a classic downtrend.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $94.74 | 50-Day MA | $113.29 |
| 10-Day MA | $95.42 | 100-Day MA | $111.08 |
| 20-Day MA | $98.95 | 200-Day MA | $125.93 |
The stock's position just 7% above its 52-week low of $90.39 and 54% below its 52-week high of $212.75 creates a high-stakes technical environment. A strong earnings beat and positive guidance on the Japan launch could trigger a sharp reversal given the oversold conditions and heavy analyst support, while any disappointment risks a test of the yearly lows. The technical setup is cautionary heading into the report, with momentum indicators uniformly negative and no meaningful support until the $90 level.